This is a working overview of Aggregation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-17 and is reviewed periodically as new material appears.
After a peptide solution is prepared, its handling conditions influence how long it remains suitable for use. Solutions are typically separated into small portions to avoid repeated freeze-thaw cycles, which can promote aggregation or precipitation. Containers are chosen to minimize adsorption, especially for peptides that are hydrophobic or present at low concentration. Some laboratories use low-binding plastic tubes or add a carrier protein, although carrier addition can interfere with later analysis. Records usually note the solvent, date, and storage temperature for traceability.
Storage stability of a reconstituted peptide depends on concentration, pH, buffer composition, and the presence of oxygen or microbial contaminants. Short-term storage is often at refrigerated temperatures, while longer-term storage may use freezing at -20 °C or -80 °C. Repeated warming and cooling can cause losses through adsorption or aggregation, so aliquots are preferred. Light-sensitive peptides require protection from ambient light. Sterile filtration may be used when microbial control is needed, but filters can adsorb peptides and reduce recovery.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Solvent selection depends on the peptide's charge, hydrophobicity, and intended application. Many lyophilized peptides dissolve readily in water, while others require a small amount of a miscible organic solvent, a dilute acid, or a dilute base before aqueous dilution. A buffer may be used when a stable pH range is known, but adding buffer salts can also promote aggregation or precipitation. Dissolution should be observed rather than assumed, because a clear solution does not prove that the peptide is monomeric or fully active. The order of solvent addition and the final volume matter for achieving the intended concentration.
| Property | Value | Notes |
|---|---|---|
| Appearance | Clear to slightly opalescent | Opalescence may indicate aggregation or undissolved material |
| Typical pH range | 3–7 for many peptides | Depends on sequence and buffer; measured after dissolution |
| Storage temperature (short term) | 2–8 °C | Refrigerated; limit repeated warming |
| Storage temperature (long term) | -20 °C or -80 °C | Freezing recommended for many research peptides |
| Common analytical method | RP-HPLC with UV detection | Purity and degradation profile can be monitored |
Reconstitution is the process of adding a liquid to a lyophilized peptide so that the dried material dissolves into solution. Lyophilization removes water from a frozen peptide preparation under reduced pressure, leaving a porous solid or powder. The dried form often has greater long-term stability than a liquid because hydrolysis and oxidation are slowed. In laboratory work, reconstitution is usually the first step before dilution, analysis, or further experiments. The result is a stock solution whose concentration depends on the volume of solvent added and the amount of peptide in the vial.
Solvent choice depends on the peptide's sequence, charge, and solubility profile. Sterile water is common for freely soluble peptides, while aqueous buffers or dilute acid or base may be needed for others. Some sequences contain hydrophobic regions that resist water alone and require a small amount of organic co-solvent. The solvent's pH can affect charge state, aggregation, and stability. Because peptides vary widely, no single universal reconstitution liquid exists, and suppliers often provide a recommended solvent based on testing of a specific lot or sequence.
After reconstitution, a peptide solution is typically stored under conditions that limit degradation. Cool temperatures slow hydrolysis and oxidation, while freezing can preserve samples for longer periods. Repeated freeze-thaw cycles may promote aggregation or precipitation, so aliquoting before freezing is a common laboratory practice. The optimal storage temperature depends on the peptide sequence, buffer composition, and expected duration. Solutions containing oxidizable residues may benefit from inert gas overlays or antioxidants, though compatibility with the specific peptide must be considered.
Aseptic technique matters because aqueous peptide solutions can support microbial growth. Sterile solvents, clean workspaces, and sterile filtration can reduce contamination. The choice of filter material and pore size must avoid peptide loss through adsorption, especially for hydrophobic or low-concentration samples. Visual inspection for particles, turbidity, or color change provides a simple initial check, but it cannot confirm identity or purity. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to verify composition and detect degradation products.
The State Union of Serbia and Montenegro (often shortened to Serbia and Montenegro), known from 1992 to 2003 as the Federal Republic of Yugoslavia (FRY) and commonly referred to as Yugoslavia, was a country in Southeastern Europe. It was established on 27 April 1992 as a federation comprising the Republic of Serbia and the Republic of Montenegro, following the breakup of the Socialist Federal Republic of Yugoslavia (SFR Yugoslavia). In February 2003, the federation was reconstituted as a state union. Following the secession of Montenegro in June 2006, Serbia proclaimed independence. Its aspirations to be the sole legal successor state to the SFR Yugoslavia were not recognized by the United Nations, following the passing of United Nations Security Council Resolution 777, which affirmed that the Socialist Federal Republic of Yugoslavia had ceased to exist, and the Federal Republic of Yugoslavia was a new state. This made the Federal Republic ineligible to inherit the Socialist Federal Republic's international legal personality, since it had dissolved, with all former republics entitled to state succession. The government of Slobodan Milošević opposed any such claims, and as such, the FR Yugoslavia was not allowed to join the United Nations. Throughout its existence, the FR Yugoslavia had a tense relationship with the international community, as economic sanctions were issued against the state during the course of the Yugoslav Wars and Kosovo War. This also resulted in hyperinflation between 1992 and 1994.
=== MicroRNAs === MicroRNAs are a factor in the development of that type of disease. MicroRNAs usually operate as a negative regulator of the expression of target proteins, and their increased concentration after biologic treatment (bDMARDs) or after anti-rheumatic drugs. The levels of miRNA before and after anti-TNFa/DMRADs combination therapy are potential novel biomarkers for predicting and monitoring the outcome. For instance, some of them were found significantly upregulated by anti-TNFa/DMRADs combination therapy. For example, miRNA-16-5p, miRNA-23-3p, miRNA125b-5p, miRNA-126-3p, miRNA-146a-5p, miRNA-223-3p. Curious fact is that only responder patients showed an increase in those miRNAs after therapy, and paralleled the reduction of TNFα, interleukin (IL)-6, IL-17, rheumatoid factor (RF), and C-reactive protein (CRP).
== Regulation and feedback == Several key enzymes can be activated through DNA transcriptional regulation on activation of SREBP (sterol regulatory element-binding protein-1 and -2). This intracellular sensor detects low cholesterol levels and stimulates endogenous production by the HMG-CoA reductase pathway, as well as increasing lipoprotein uptake by up-regulating the LDL-receptor. Regulation of this pathway is also achieved by controlling the rate of translation of the mRNA, degradation of reductase and phosphorylation.
Sources: en.wikipedia.org
complementarity A property of nucleic acid biopolymers whereby two polymeric chains or "strands" aligned antiparallel to each other will tend to form base pairs consisting of hydrogen bonds between the individual nucleobases comprising each chain, with each type of nucleobase pairing almost exclusively with one other type of nucleobase; e.g. in double-stranded DNA molecules, A pairs only with T and C pairs only with G. Strands that are paired in such a way, and the bases themselves, are said to be complementary. The degree of complementarity between two strands strongly influences the stability of the duplex molecule; certain sequences may also be internally complementary, which can result in a single strand binding to itself. Complementarity is fundamental to the mechanisms governing DNA replication, transcription, and DNA repair.
In this experiment it was shown that the overall DFE is bimodal, with a cluster of neutral mutations, and a broad distribution of deleterious mutations. Though relatively few mutations are advantageous, those that are play an important role in evolutionary changes. Like neutral mutations, weakly selected advantageous mutations can be lost due to random genetic drift, but strongly selected advantageous mutations are more likely to be fixed. Knowing the DFE of advantageous mutations may lead to increased ability to predict the evolutionary dynamics. Theoretical work on the DFE for advantageous mutations has been done by John H. Gillespie and H. Allen Orr. They proposed that the distribution for advantageous mutations should be exponential under a wide range of conditions, which, in general, has been supported by experimental studies, at least for strongly selected advantageous mutations. In general, it is accepted that the majority of mutations are neutral or deleterious, with advantageous mutations being rare; however, the proportion of types of mutations varies between species. This indicates two important points: first, the proportion of effectively neutral mutations is likely to vary between species, resulting from dependence on effective population size; second, the average effect of deleterious mutations varies dramatically between species. In addition, the DFE also differs between coding regions and noncoding regions, with the DFE of noncoding DNA containing more weakly selected mutations.
=== Differences with the government === Heseltine's resignation in January 1986 had been just before the only occasion on which the Poll Tax was discussed in Cabinet. He spoke against the tax when it was enacted into law in 1987–1988, but abstained rather than voting against as Edward Heath did, although he voted for Michael Mates' amendment which tried to introduce an element of banding according to ability to pay. Heseltine remained aloof from factional plotting in the Commons, and voted with the left-wing Lollard faction in backbench committee elections. Heseltine later said that he regretted resigning from the Cabinet in 1986, as he subsequently often wondered if he and Nigel Lawson might have been able to persuade Thatcher to abandon the tax. Heseltine clashed bitterly at this time with his former friend Nicholas Ridley. Ridley was a Eurosceptic, a free marketer, a champion of the poll tax and a key ally of Thatcher. Heseltine argued that there was too much green belt building (although in fact only slightly more so than he had himself authorised as Environment Secretary) and stated that as a property developer he had never built on a "green" site, forgetting that he had done so in Tenterden in the early 1960s.
Sources: en.wikipedia.org
J. League Manager of the Year: 1995 Onze d'Or Coach of The Year: 2000, 2002, 2003, 2004 Premier League Manager of the Season: 1997–98, 2001–02, 2003–04 LMA Manager of the Year: 2001–02, 2003–04 BBC Sports Personality of the Year Coach Award: 2002, 2004 London Football Awards – Outstanding Contribution to a London Club: 2015 World Soccer Manager of the Year: 1998 FWA Tribute Award: 2005 English Football Hall of Fame: 2006 France Football Manager of the Year: 2008 IFFHS World Coach of the Decade: 2001–2010 Facebook FA Premier League Manager of the Year: 2014–15 Premier League Manager of the Month: March 1998, April 1998, October 2000, April 2002, September 2002, August 2003, February 2004, August 2004, September 2007, December 2007, February 2011, February 2012, September 2013, March 2015, October 2015 France Football 32nd Greatest Manager of All Time: 2019 World Soccer 36th Greatest Manager of All Time: 2013 Laureus Lifetime Achievement Award: 2019 Premier League Hall of Fame: 2023 Orders
John Barry Larson (born July 22, 1948) is an American politician and businessman who has been serving as the U.S. representative for Connecticut's 1st congressional district since 1999. The district is based in the state capital, Hartford. A member of the Democratic Party, Larson chaired the House Democratic Caucus during the 111th and 112th United States Congress. Larson was first elected to Congress in 1998, serving fourteen consecutive terms in the House. He attempted to seek a fifteenth term, but he was defeated in the 2026 Democratic primary by former Hartford mayor Luke Bronin.
== Antioxidant effect == Lithium ascorbate normalizes the neurohumoral status with similar physiological effects at the level of the antioxidant system of the animal organism, reducing the blood levels of the main stress hormone adrenaline, norepinephrine and cortisol. The addition of lithium ascorbate to the diet of pregnant sows of Irish Landrace breed led to an increase in the antioxidant status of farrowing sows and a decrease in the level of lipid peroxidation. The use of lithium ascorbate caused a significant increase in the level of reduced glutathione by 21% and a decrease in the level of malondialdehyde by 60%. The introduction of lithium ascorbate with feed to sows and fattening pigs at dosages of 10, 5 and 2 mg/kg maintained the dynamics of stress hormones at the physiological level. In pregnant sows, it normalizes the concentration of progesterone, and has a positive effect on reproductive function, non-specific immunity, being a protector against technological and spontaneous stressors. Lithium ascorbate had a positive effect on lipid-cholesterol metabolism, antioxidant status, increased the level of general reactivity of the body, increased the level of hemoglobin, erythrocytes and lymphocytes, mobilized energy resources, enhanced the bactericidal and phagocytic activity of cellular elements, contributed to the performance of protective functions by gamma globulins in the system of nonspecific immunity. The combined intake of carnosine and lithium ascorbate contributed to the reduction of ethanol-induced oxidative damage to plasma proteins and lipids.
Sources: en.wikipedia.org
Refrigeration is common for short-term use, while freezing at -20 °C or -80 °C is common for longer periods. Aliquots reduce repeated temperature changes. Exact conditions depend on the peptide and buffer.
Repeated freeze-thaw cycles can cause aggregation, precipitation, or adsorption losses. Dividing a solution into single-use portions limits those changes. The practice also makes handling more consistent.
Undissolved powder, aggregated peptide, or precipitated buffer salts can produce visible particles. Some particles appear only after freezing or pH changes. Filtration and analytical checks can help identify the source.
It means adding liquid to a lyophilized peptide powder so it dissolves into solution. The dry powder is not a finished liquid product, and the resulting concentration depends on the volume added. Complete dissolution should be visually confirmed before use.